Background Men with high-risk non-metastatic prostate cancer are treated with androgen-deprivation
therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new …

Background STAMPEDE has previously reported that radiotherapy (RT) to the prostate
improved overall survival (OS) for patients with newly diagnosed prostate cancer with low …

Purpose Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both
improve survival when commenced alongside standard of care (SOC) androgen deprivation …

Combined hepatocellular cholangiocarcinoma (CC) is a rare and aggressive primary hepatic
malignancy with significant histological and biological heterogeneity. It presents with more …

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in
STAMPEDE, a multiarm, multistage platform trial in men starting long‐term hormone therapy …

Background Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or
enzalutamide added at the start of androgen deprivation therapy improves outcomes for …

Background: This study aims to compare the outcomes of COVID-19-positive disease in
patients with a history of cancer to those without. Methods: We retrospectively collected clinical …

14 Background: Docetaxel (DOC) and abiraterone (ABI) both improve overall survival (OS) in
men with locally advanced or metastatic hormone-sensitive prostate cancer (HSPC) but no …

Background STAMPEDE previously reported adding upfront docetaxel improved overall
survival for prostate cancer patients starting long-term androgen deprivation therapy. We report …

Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves
survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy…